The Triangle of Diabetes Care is an emerging treatment strategy that is centred around three diabetes management targets — reaching all three can help improve outcomes for patients with Type 1 and Type 2 diabetes. When used with the FreeStyle Libre system, you can help your patients hit targets in all three areas using the glucose data from their sensor to inform your treatment plan.
The FreeStyle Libre system displays trend arrows to show your patients where their glucose levels are heading. This means that even in the absence of hypoglycaemic symptoms, your patient can know if their glucose levels are falling and take the appropriate action. Current Time in Range consensus suggests less than <3.9mmol/L & less than 4% including 1% <3mmol/L of time should be spent below those ranges for adults with Type 1 and Type 2 diabetes who are not pregnant, not older, or at risk.3
In separate clinical trials for those with Type 1 and Type 2 diabetes, compared to SMBG testing, FreeStyle Libre system users significantly reduced the amount of time that their glucose dipped into the hypoglycaemic zone (<3.9 mmol/L) by 38% and 43% respectively4,5.
Find out more about minimising hypoglycaemia in our Healthcare Professional Education modules about the Triangle of Diabetes Care and Targeting Hypoglycaemia.
Limit glucose variability
The FreeStyle Libre portfolio empowers patients to hit targets on each of the three sides of the Triangle of Diabetes Care and improve their overall glucose control. Even if one goal cannot be reached, an improvement of one or both of the other goals will have a positive effect on the overall health of your patients.
We offer various on-demand webinars for Healthcare Professionals including a spotlight on hypoglycaemia.
Learn more about the Triangle of Diabetes Care and the FreeStyle Libre Portfolio through our Healthcare Professional education modules.
Find out more about living with diabetes and how the FreeStyle Libre Portfolio can help patients better manage their diabetes using data from real users.
References & Disclaimers
1. Lang, et al. Expanded Real-world Use Confirms Strong Association between Frequency of Flash Glucose Monitoring and Glucose Control. Advanced Technologies & Treatments for Diabetes Meeting. Berlin. February 20-23, 2019. Diabetes Technology & Therapeutics, Volume 21, Supplement 1, 2019.
2. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 50, 1140–1147 (2007). https://doi.org/10.1007/s00125-007-0599-y.
3. Battelino, T. Diabetes Care (2019): https://doi.org/10.2337/dci19-0028
4. Bolinder, J. The Lancet (2016): https://doi.org/10.1016/S0140-6736(16)31535-5.
5. Haak, T. Diabetes Therapy (2017): https://doi.org/10.1007/s13300-016-0223-6.
6. Ceriello A. et al, Lancet Diabetes Endocrinol 2019 : http://dx.doi.org/10.1016/S2213-8587(18)30136-0
7. Kilpatrick, E.S., Rigby, A.S. & Atkin, S.L. Mean blood glucose compared with HbA1c in the prediction of cardiovascular disease in patients with type 1 diabetes. Diabetologia 51, 365–371 (2008). https://doi.org/10.1007/s00125-007-0883-x
8. Campbell, Fiona M., et al. "Outcomes of Using Flash Glucose Monitoring technology by Children and young people with Type 1 Diabetes in a Single Arm Study." Pediatric Diabetes 19, no. 7 (2018): 1294-1301. https://doi.org/10.1111/pedi.12735.
The "Yes" link below will take you to a website other than Abbott Laboratories. Links to other websites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the content of such websites or any link contained in such websites. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement by Abbott Laboratories of the site.
Do you want to leave this page?
This is a product-specific website intended for HCPs of Ireland. If you live in another country, please contact your local Abbott office to obtain the correct product information for your country of residence.